Genetics of Platelet Glycoprotein Receptors: Risk of Thrombotic Events and Pharmacogenetic Implications. Export

@article{citeulike:159050, abstract = {SUMMARY: Platelet aggregation and coronary thrombosis have a central role in the development of acute coronary syndromes and myocardial infarction (MI). Therapies aimed at inhibiting platelet aggregation have shown great benefit in individuals with coronary disease or with multiple risk factors for coronary disease. Genetic variation in platelet surface receptors mediating thrombus formation has been suggested to be associated with platelet hyperreactivity, with increased risk of MI and possibly with the benefit received from various antithrombotic drug treatments. This review focuses on discrepancies and their likely explanations in studies on platelet glycoprotein genetics. Current knowledge on important issues concerning coronary event phenotypes and pharmacogenetics is analyzed. Possible future applicability of these data to patient treatment is also discussed.}, address = {Tampere University Hospital, Research Unit and Medical School, University of Tampere, Tampere University Hospital, and National Public Health Institute, Helsinki, Finland Satakunta Central Hospital, Pori, Finland. jussi.mikkelsson@dnainternet.net; jussi.mikkelsson@kolumbus.fl.}, author = {Mikkelsson, Jussi and Perola, Markus and Karhunen, Pekka J.}, citeulike-article-id = {159050}, citeulike-linkout-0 = {http://view.ncbi.nlm.nih.gov/pubmed/15821818}, citeulike-linkout-1 = {http://www.hubmed.org/display.cgi?uids=15821818}, issn = {1076-0296}, journal = {Clin Appl Thromb Hemost}, keywords = {blood, factors, genetics, glycoproteins, pharmacogenetics, platelets, receptors, risk, thrombosis}, month = {April}, number = {2}, pages = {113--125}, posted-at = {2005-04-12 12:52:54}, priority = {2}, title = {Genetics of Platelet Glycoprotein Receptors: Risk of Thrombotic Events and Pharmacogenetic Implications.}, url = {http://view.ncbi.nlm.nih.gov/pubmed/15821818}, volume = {11}, year = {2005} }

TY - JOUR ID - citeulike:159050 L3 - citeulike-article-id:159050 N2 - SUMMARY: Platelet aggregation and coronary thrombosis have a central role in the development of acute coronary syndromes and myocardial infarction (MI). Therapies aimed at inhibiting platelet aggregation have shown great benefit in individuals with coronary disease or with multiple risk factors for coronary disease. Genetic variation in platelet surface receptors mediating thrombus formation has been suggested to be associated with platelet hyperreactivity, with increased risk of MI and possibly with the benefit received from various antithrombotic drug treatments. This review focuses on discrepancies and their likely explanations in studies on platelet glycoprotein genetics. Current knowledge on important issues concerning coronary event phenotypes and pharmacogenetics is analyzed. Possible future applicability of these data to patient treatment is also discussed. IS - 2 JF - Clin Appl Thromb Hemost SN - 1076-0296 AD - Tampere University Hospital, Research Unit and Medical School, University of Tampere, Tampere University Hospital, and National Public Health Institute, Helsinki, Finland Satakunta Central Hospital, Pori, Finland. jussi.mikkelsson@dnainternet.net; jussi.mikkelsson@kolumbus.fl. EP - 125 TI - Genetics of Platelet Glycoprotein Receptors: Risk of Thrombotic Events and Pharmacogenetic Implications. VL - 11 SP - 113 KW - blood KW - factors KW - genetics KW - glycoproteins KW - pharmacogenetics KW - platelets KW - receptors KW - risk KW - thrombosis AU - Mikkelsson, Jussi AU - Perola, Markus AU - Karhunen, Pekka PY - 2005/04// UR - http://view.ncbi.nlm.nih.gov/pubmed/15821818 ER -